1,792 reports of this reaction
1.6% of all UPADACITINIB reports
#10 most reported adverse reaction
HEADACHE is the #10 most commonly reported adverse reaction for UPADACITINIB, manufactured by AbbVie Inc.. There are 1,792 FDA adverse event reports linking UPADACITINIB to HEADACHE. This represents approximately 1.6% of all 110,317 adverse event reports for this drug.
UPADACITINIB has an overall safety score of 85 out of 100. Patients taking UPADACITINIB who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for UPADACITINIB, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for UPADACITINIB:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 1,792 FDA reports for UPADACITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 1.6% of all adverse event reports for UPADACITINIB, making it a notable side effect.
If you experience headache while taking UPADACITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.